Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986148 in advanced solid tumors
NCT02884726Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2016
- Primary completion
- Sep 2017
- Modality
- Antibody-Drug Conjugates (ADCs), Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMS-986148 in solid tumor (advanced stage) and metastatic solid tumors, sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Adverse Events, Incidence of Serious Adverse Events and 2 more. Started Oct 2016; status: completed.
02
Drugs
BMS-986148
03
Conditions
solid tumor (advanced stage)metastatic solid tumors
Beyond the preview
Go deeper on NCT02884726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02884726.